1. Introduction
===============

The prevalence of diabetes mellitus and type 2 diabetes mellitus, in particular, has been increasing worldwide because of the high rates of obesity. Many studies have investigated methods for reducing the incidence of type 2 diabetes, with primary recommendations including improved diet and increased exercise.^\[[@R1],[@R2]\]^ Oral hypoglycemics are first-line drugs against type 2 diabetes mellitus when diet and exercise fail to control blood glucose levels. Patients with type 2 diabetes mellitus have been shown to have higher bone densities^\[[@R3]--[@R6]\]^ and possibly lower fracture risks than general population.^\[[@R7]\]^ However, many studies have shown an association between type 2 diabetes mellitus and fracture risk.^\[[@R8],[@R9]\]^ The increased risk might be related to other factors such as complications of diabetes, risk of falling, and use of antidiabetic medications. Thiazolidinediones, including pioglitazone and rosiglitazone, are a relatively new and effective class of oral antidiabetic agents that have gained wide use in clinical conditions characterized by insulin resistance. Thiazolidinediones are ligands of the peroxisome proliferator-activated receptor gamma nuclear transcription factor. Various studies have shown that thiazolidinedione use decreases bone mineral density and elevates fracture risk.^\[[@R10]--[@R13]\]^ A meta-analysis showed that rosiglitazone and pioglitazone are associated with a significantly increased fracture risk.^\[[@R14]\]^

Hip fractures, which constitute a common health problem with many proposed and established risk factors,^\[[@R15]\]^ are associated with significant morbidity and mortality rates and reduction in the quality of life of older individuals. Patients with type 2 diabetes mellitus and hip fractures have a significantly longer mean duration of hospitalization, pressure sores, and cardiovascular complications.^\[[@R16]\]^

Given the paucity of information regarding the association between thiazolidinedione use and hip fracture risk in Asian countries, the present population-based case--control study was conducted to investigate this particular association among the elderly in Taiwan.

2. Methods
==========

2.1. Data source
----------------

Taiwan is an independent country with more than 23 million residents.^\[[@R17]--[@R24]\]^ A population-based case--control study was conducted using the database of the Taiwan National Health Insurance Program. This insurance program began in March 1995 and has covered 99% of the 23 million residents of Taiwan.^\[[@R25]\]^ Details of the program can be found in previous studies.^\[[@R26]--[@R30]\]^ The present study was approved by the Research Ethics Committee of China Medical University (CMUH-104-REC2--115).

2.2. Sampled participants and comorbidities
-------------------------------------------

Subjects with type 2 diabetes, ≥65 years of age and who were newly diagnosed with hip fractures (ICD-9 code 820) in 2000 to 2013 were included as cases. The diagnosis date of the hip fracture was defined as the index date. Subjects with type 2 diabetes who were not diagnosed with hip fractures were randomly selected as controls from the same database. Both cases and controls were matched for sex, age (per 5 years), comorbidities, and index date. Comorbidities potentially related to hip fractures before the index date included alcohol-related, cardiovascular, chronic kidney, and chronic obstructive pulmonary diseases; hyperlipidemia; hypertension; and osteoporosis. The diagnostic accuracy of comorbidities based on ICD-9 codes has been well examined in previous studies.^\[[@R31]--[@R35]\]^

2.3. Use of thiazolidinediones and other hypoglycemic agents
------------------------------------------------------------

Thiazolidinediones available in Taiwan include pioglitazone and rosiglitazone, whereas other antidiabetic agents available in Taiwan include sulfonylurea, metformin, alpha-glucosidase inhibitors, dipeptidyl peptidase 4 inhibitors, and insulin. The definition of medication use was adapted from previous studies.^\[[@R36]--[@R41]\]^ To decrease biased results, subjects whose last thiazolidinedione tablet was noted to be scheduled at ≥31 days before the index date were excluded from the study. Therefore, the current use of thiazolidinedione was defined as subjects whose last thiazolidinedione tablet was noted to be scheduled at ≤30 days before the index date or those still taking thiazolidinedione tablets upon the diagnosis of a hip fracture diagnosis. Nonuse of thiazolidinediones was defined as the lack of a thiazolidinedione prescription. Medication history regarding the use of other hypoglycemic agents was also included.

2.4. Statistical analysis
-------------------------

First, the distribution of demographic status, use of thiazolidinediones and other hypoglycemic agents, and comorbidities between the cases and controls were compared using the chi-square test and Fisher exact test for categorized variables. Student *t* test was performed to examine the differences in mean age and mean duration of type 2 diabetes between the cases and controls. Univariable and multivariable unconditional logistic regression analyses were performed to calculate the odds ratio (OR) and 95% confidence interval (CI) to determine the association between thiazolidinedione use and hip fracture risk. A multivariable analysis with adjustments for the duration of type 2 diabetes mellitus was performed. The dose-dependent effects of thiazolidinedione were analyzed among current users. The average daily dose of thiazolidinedione was calculated by dividing the total quantity of thiazolidinedione by the total number of days for which it was administered. The average daily dose was divided into 2 levels according to median doses of \<15 and ≥15 mg. All analyses were performed using SAS statistical software (version 9.2; SAS Institute, Inc., Cary, NC), and results showing 2-tailed *P* values of \< .05 were considered statistically significant.

3. Results
==========

3.1. Descriptive characteristics of the study population
--------------------------------------------------------

In total, 603 cases with newly diagnosed hip fractures in 2000 to 2013 and 603 controls without hip fractures (Table [1](#T1){ref-type="table"}) were included. Both cases and controls had similar sex and age distributions. The mean ages (standard deviation) of the cases and controls were 76.8 (6.5) and 76.7 (6.2) years, respectively, without a statistical significance (*t* test, *P* = .8). The cases were more likely to have higher proportions of current thiazolidinedione use (9.0% vs 4.6%; chi-square test, *P* = .003) and longer durations of type 2 diabetes mellitus (4.8 vs 3.9 years; *t* test, *P* = .001) than the controls. No significant differences in other comorbidities and the use of other hypoglycemic agents were observed between the cases and controls (chi-square test, *P* \> .05).
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Characteristics of cases with hip fracture and controls in older people.
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3.2. Association between hip fracture risk and thiazolidinedione use
--------------------------------------------------------------------

After adjusting for covariables, multivariable logistic regression analysis revealed that the adjusted OR for hip fracture risk was 1.64 in subjects currently using thiazolidinediones (95% CI, 1.01--2.67) compared with that in those who never used the drug (Table [2](#T2){ref-type="table"}). The duration of type 2 diabetes was another factor significantly associated with hip fracture risk (annually; adjusted OR: 1.08; 95% CI, 1.04--1.12).
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OR and 95% CI of hip fracture associated with thiazolidinediones use and comorbidities in older people.
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3.3. Association between hip fracture risk and average daily dose in current users of thiazolidinediones
--------------------------------------------------------------------------------------------------------

Further analysis on the dose-dependent effect of thiazolidinediones was conducted among current users. After adjusting for covariables, the adjusted OR for hip fracture risk was 1.46 in subjects with an average daily thiazolidinedione dose of \<15 mg (95% CI, 0.80--2.66) and 6.22 in those with an average daily thiazolidinedione dose of ≥15 mg (95% CI, 2.32--16.7) compared with that in those who never used thiazolidinediones (Table [3](#T3){ref-type="table"}). These results suggest that thiazolidinedione use has a dose-dependent effect on hip fracture risk.
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Average daily dose of current use of thiazolidinediones and risk of hip fracture in older people.
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4. Discussion
=============

The most significant findings of the present study included the association between the current use of thiazolidinediones and a 1.64-fold increase in the hip fracture risk in older Taiwanese individuals with type 2 diabetes. A meta-analysis showed that patients using rosiglitazone and pioglitazone had a 1.5-fold increase in fracture risk compared with those using other antidiabetic drugs.^\[[@R14]\]^ Habib et al^\[[@R42]\]^ conducted a cohort study in which thiazolidinedione use was observed to be associated with a 1.4-fold increase in fracture risk compared with other antidiabetic medication use. Another cohort study^\[[@R43]\]^ that compared thiazolidinedione use with metformin use reported a 1.3-fold increase in fracture risk. Using a self-controlled case series design to compare periods of exposure and nonexposure to thiazolidinediones, Douglas et al^\[[@R44]\]^ found a within-person rate ratio of 1.43 for fracture risk. Several studies have conducted that thiazolidinediones may exert unwanted effects on bone, resulting in attenuated osteoblast number and increased osteoclastogenesis.^\[[@R12],[@R45]--[@R48]\]^ The peroxisome proliferator-activated receptor-gamma (PPAR-γ) is a DNA-binding nuclear hormone receptor that regulates glucose metabolism and bone mass. PPAR-γ receptors are most abundant in adipocytes and regulate their differentiation and function. The increased expression of PPAR-γ led to changes in marrow structure and function, such as decrease in osteoblast number, increase in marrow fat cells and osteoclast number, and loss of the multipotential character of bone marrow mesenchymal stem cells. Thiazolidinediones are ligands for PPAR-γ. When rosiglitazone is added to bone marrow cultures, a shift in the flow of mesenchymal precursor cells from osteoblastic to adipogenic lineages mediated by the activation of PPAR-γ has been shown to result in attenuated osteoblastic bone formation and accelerated bone loss.^\[[@R49],[@R50]\]^

In addition to thiazolidinedione use, the severity and duration of type 2 diabetes mellitus have been shown to be associated with fracture risk.^\[[@R8],[@R9]\]^ Our study showed that the duration of type 2 diabetes is a factor significantly associated with hip fracture risk (annually; adjusted OR, 1.08; 95% CI, 1.04--1.12). There are various mechanisms that may be involved in the increased fracture risk. McNair P et al revealed that bone mineral content was inversely correlated with fasting blood glucose, and urinary excretion rates of calcium and phosphorus correlated positively with the degree of hyperglycemia.^\[[@R51]\]^ The skeletal calcium loss corresponded to the excess of urinary calcium excretion during the phase of bone mineral content reduction. High blood glucose in patients with diabetes may lead to lower intestinal absorption of calcium,^\[[@R52]\]^ altered in serum of vitamin D metabolites,^\[[@R53],[@R54]\]^ and might have a direct toxic effect on bone cells.^\[[@R55],[@R56]\]^ Inaba M et al revealed that impaired parathyroid hormone secretion may be responsible for the low bone turnover in hemodialyzed patients with diabetes.^\[[@R57]\]^ Several studies conducted that complications of diabetes mellitus (retinopathy, neuropathy, and angiopathy) may also increase fracture risk.^\[[@R58]--[@R61]\]^

Meier et al showed that the adjusted OR for any fracture during the current use of ≥15 thiazolidinedione prescriptions was 2.86 (95% CI, 1.57--5.22) compared with that during nonuse.^\[[@R62]\]^ The present study found that the adjusted ORs for hip fracture risk were 6.22 and only 1.46 for subjects with average daily thiazolidinedione dose of ≥15 mg (95% CI, 2.32--16.7) and \<15 mg (95% CI, 0.80--2.66), respectively, compared with that for subjects who never used the drug. These results show that thiazolidinedione use may have a dose-dependent effect on hip fracture risk. Our interpretation of these results suggests that although thiazolidinedione use is probably the most important factor in the association between thiazolidinediones and fracture risk, the severity and duration of the underlying disease also play a role.

Some strengths of the present study should be documented. This study utilized a hospitalization dataset with more accurate diagnoses of hip fractures. Comorbidities based on ICD-9 codes have been carefully reviewed in previous studies. Moreover, the study design and statistical methods have been well conducted, and the results are reasonable and provide updated evidence on this issue.

Some limitations of this present study should be discussed. First, to decrease the biased results, subjects whose last remaining thiazolidinedione tablet was noted to be scheduled at ≥31 days before the index date were excluded from the study. Because of this strict inclusion criterion, only 603 cases and 603 controls were included in the present study. Second, because of the inherent limitations of the used database, whether patients really took thiazolidinediones could not be ascertained although thiazolidinedione prescriptions were included instead. Nonetheless, it is well known that getting a prescription is not equivalent to using it. Third, bone densitometry was not performed. Therefore, whether the increased fracture risk was mediated by a reduced bone mass in patients with diabetes could not be evaluated. Fourth, it has been previously recognized that patients with type 2 diabetes mellitus have a higher body mass index than the general population^\[[@R63]\]^ and that a higher body mass index is protective against fractures.^\[[@R64]\]^ This may have led to an underestimation of the true association between thiazolidinedione use in type 2 diabetes mellitus and fracture risk. Fifth, a clinical measure of diabetes severity, such as HbA1c, was not available, which could have been an improvement over the prior diabetic hospitalization variables used. Sixth, our study did not include certain demographic or lifestyle factors. It is possible that certain demographic or lifestyle factors, such as the socioeconomic status, dietary habits, and physical activity are associated with fracture risks and antidiabetic drug use.

We conclude that the use of thiazolidinediones is associated with a 64% increase, particularly in a dose-dependent manner, in hip fracture risk in older Taiwanese individuals with type 2 diabetes. Clinicians should consider the possibility of thiazolidinedione-associated hip fractures among older patients with type 2 diabetes using thiazolidinediones.

Abbreviation: ICD-9 code = International Classification of Diseases Ninth Revision Clinical Modification.
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